The response to CZP and ADA, as measured by CDAI and SDAI, was also greater in patients with RA treated with CZP compared with ADA in patients with RF levels >204 IU/ml, but not in those with RF levels ≤204 IU/ml. This evidence concerns the gene ADA and rheumatoid arthritis.